Have a personal or library account? Click to login
SDF-1 and its receptor in the ventricles of rat with monocrotaline-induced pulmonary hypertension Cover

SDF-1 and its receptor in the ventricles of rat with monocrotaline-induced pulmonary hypertension

Open Access
|Dec 2018

References

  1. [1] Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cellderived factor 1 (SDF-1). J Exp Med. 1996;184(3):1101-9.10.1084/jem.184.3.110121927989064327
  2. [2] Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest. 2009;135(3):794-804.10.1378/chest.08-049219265089
  3. [3] Burke DL, Frid MG, Kunrath CL et al. Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. Am J Physiol Lung Cell Mol Physiol. 2009;297(2):L238-50.10.1152/ajplung.90591.2008274280019465514
  4. [4] Doka G, Malikova E, Galkova K et al. Downregulation of myogenic microRNAs in sub-chronic but not in sub-acute model of daunorubicin-induced cardiomyopathy. Mol Cell Biochem. 2017;432(1-2):79-89.10.1007/s11010-017-2999-828303410
  5. [5] Gambaryan N, Perros F, Montani D et al. Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension. Eur Respir J. 2011;37(6):1392-9.10.1183/09031936.0004571020884740
  6. [6] Galiè N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Rev Esp Cardiol (Engl Ed). 2016;69(2):177.10.1016/j.recesp.2016.01.002
  7. [7] Gomez-Arroyo JG, Farkas L, Alhussaini AA et al. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol. 2012;302(4):L363-9.10.1152/ajplung.00212.201121964406
  8. [8] Hoeper MM, Bogaard HJ, Condliffe R et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62(25 Suppl):D42-50.10.1016/j.jacc.2013.10.03224355641
  9. [9] Jackson EK, Zhang Y, Gillespie DD, Zhu X, Cheng D, Jackson TC. SDF-1α (Stromal Cell-Derived Factor 1α) Induces Cardiac Fibroblasts, Renal Microvascular Smooth Muscle Cells, and Glomerular Mesangial Cells to Proliferate, Cause Hypertrophy, and Produce Collagen. J Am Heart Assoc. 2017;6(11).10.1161/JAHA.117.007253572179429114002
  10. [10] Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT. Pulmonary arterial hypertension: the clinical syndrome. Circ Res. 2014;115(1):115-30.10.1161/CIRCRESAHA.115.301146409668624951762
  11. [11] McCullagh BN, Costello CM, Li L et al. Elevated plasma CXCL12α is associated with a poorer prognosis in pulmonary arterial hypertension. PLoS One. 2015;10(4):e0123709.10.1371/journal.pone.0123709439183325856504
  12. [12] Schioppa T, Uranchimeg B, Saccani A et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med. 2003;198(9):1391-402.10.1084/jem.20030267219424814597738
  13. [13] Shao S, Cai W, Sheng J, Yin L. Role of SDF-1 and Wnt signaling pathway in the myocardial fibrosis of hypertensive rats. Am J Transl Res. 2015;7(8):1345-56.
  14. [14] Srankova J, Doka G, Pivackova L et al. Daunorubicin Down-Regulates the Expression of Stem Cell Markers and Factors Involved in Stem Cell Migration and Homing in Rat Heart in Subchronic but not Acute Cardiomyopathy. Basic Clin Pharmacol Toxicol. 2016;119(5):443-452.10.1111/bcpt.1260627090888
  15. [15] Sutendra G, Dromparis P, Paulin R et al. A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. J Mol Med (Berl). 2013;91(11):1315-27.10.1007/s00109-013-1059-423846254
  16. [16] Yu L, Hales CA. Effect of chemokine receptor CXCR4 on hypoxiainduced pulmonary hypertension and vascular remodeling in rats. Respir Res. 2011;12:21.10.1186/1465-9921-12-21304239821294880
  17. [17] Wang ER, Jarrah AA, Benard L et al. Deletion of CXCR4 in cardiomyocytes exacerbates cardiac dysfunction following isoproterenol administration. Gene Ther. 2014;21(5):496-506.10.1038/gt.2014.23401611224646609
Language: English
Page range: 23 - 26
Submitted on: May 2, 2018
Accepted on: Jun 4, 2018
Published on: Dec 7, 2018
Published by: Comenius University in Bratislava, Faculty of Pharmacy
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Related subjects:

© 2018 J. Veteskova, M. Obsivan, Z. Kmecova, M. Radik, J. Srankova, E. Malikova, J. Klimas, P. Krenek, published by Comenius University in Bratislava, Faculty of Pharmacy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.